Tibolon Aristo (Tibolone 2.5 mg)

What Is Tibolon Aristo and What Is It Used For?

Tibolon Aristo is a once-daily tablet containing 2.5 mg of tibolone, a synthetic steroid that behaves like a mild form of estrogen, progestogen and androgen in different tissues of the body. It is used to relieve menopausal symptoms in women whose last period was at least 12 months ago and to help prevent osteoporosis in postmenopausal women at high risk of fractures.

Tibolone is classified by the World Health Organization under ATC code G03CX01 ("other estrogens") and is widely described in scientific literature as a Selective Tissue Estrogenic Activity Regulator (STEAR). This name reflects the way the drug, after being taken by mouth and metabolised in the gut and liver, produces different effects in different tissues. In the brain, bones and vagina it acts predominantly through its 3-alpha- and 3-beta-hydroxy metabolites, which bind to the estrogen receptor and mimic the beneficial effects of estrogen on hot flushes, mood, vaginal lining and bone density. In the endometrium and breast, however, the delta-4 isomer of tibolone has a more progestogenic and weakly androgenic profile, which is intended to minimise stimulation of the uterine lining without needing a separate progestogen tablet.

Tibolon Aristo is indicated for two main clinical situations. The first is the treatment of estrogen-deficiency symptoms in postmenopausal women more than one year after their last natural menstrual period. Typical symptoms that respond to tibolone include hot flushes and night sweats (vasomotor symptoms), sleep disturbance, tiredness, low mood or irritability related to hormone change, vaginal dryness, discomfort during intercourse (dyspareunia) and, in some women, reduced libido. The second indication is the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or have contraindications to, other medicines approved for osteoporosis prevention such as bisphosphonates, denosumab or selective estrogen receptor modulators.

Tibolone differs from "conventional" hormone replacement therapy (HRT) in an important practical way: because its metabolites cover both estrogenic and progestogenic needs, it is given as a single daily tablet without the need for an added progestogen, even in women who still have a uterus. This makes dosing simpler and, for many women, reduces cyclical bleeding and breast tenderness that can occur with combined estrogen + progestogen regimens. Tibolone has been in clinical use in Europe and many other countries since 1988, and over the decades large randomised trials such as the LIFT and LIBERATE studies, together with observational data from the Million Women Study, have clarified both its benefits and its risks.

Tibolon Aristo is supplied by Aristo Pharma GmbH, a generic manufacturer that produces a pharmaceutical equivalent of the original brand, Livial®, which was developed by Organon (now MSD). Generic tibolone products, including Tibolon Aristo, must meet the same quality, bioequivalence and safety standards as the originator. The active substance, the 2.5 mg strength, the pharmacokinetic profile and the approved indications are therefore identical between Tibolon Aristo and the originator brand, and prescribers can switch between them without changing the clinical approach. However, tibolone is not approved by the U.S. Food and Drug Administration (FDA) and is therefore not commercially available in the United States; in that market, conventional HRT regimens or non-hormonal options such as fezolinetant are used instead.

What Should You Know Before Taking Tibolon Aristo?

Before starting Tibolon Aristo, your doctor will take a full medical and family history, perform a clinical breast examination and review your mammogram status, check your blood pressure and screen for cardiovascular and thrombotic risk. There are important conditions in which tibolone must not be used, and others where regular monitoring is required. Always give your doctor a full list of all medicines, supplements and herbal remedies you are taking.

Contraindications

Tibolon Aristo must not be used if any of the following apply to you. These are absolute contraindications: starting tibolone in these situations can cause serious or life-threatening harm.

• Breast cancer: Known, past or suspected breast cancer — tibolone significantly increased the rate of breast cancer recurrence in the LIBERATE trial and is contraindicated at any point in a woman's life after a breast cancer diagnosis
• Other estrogen-dependent malignancies: Known or suspected cancer of the endometrium (lining of the womb) or other hormone-dependent tumours
• Undiagnosed genital bleeding: Any vaginal bleeding that has not been investigated must be clarified before tibolone is started, because it may be an early sign of endometrial hyperplasia or cancer
• Untreated endometrial hyperplasia: Tibolone is not a treatment for endometrial hyperplasia and may worsen it
• Venous thromboembolism: Previous or current deep vein thrombosis (DVT) or pulmonary embolism (PE), or a known thrombophilic disorder such as protein C, protein S or antithrombin deficiency
• Active or recent arterial thromboembolic disease: Such as angina, myocardial infarction (heart attack), transient ischaemic attack or stroke
• Acute liver disease, or a history of liver disease with persistently abnormal liver function tests
• Porphyria: Tibolone can trigger acute porphyric attacks in susceptible individuals
• Pregnancy and breastfeeding: Tibolone must not be used during pregnancy or while breastfeeding
• Hypersensitivity: Known allergy to tibolone or to any of the excipients in the tablet

Warnings and Precautions

Before your doctor prescribes Tibolon Aristo, the potential benefits and risks will be discussed in the context of your individual profile. At every annual review your prescriber will reconsider whether continuing treatment is still appropriate. You should tell your doctor and ask for a cautious approach, closer monitoring, or alternative treatment if any of the following apply:

• Age over 60: Tibolone is generally not recommended as a first-line option for menopausal symptom relief in women over 60 years of age because the absolute risks of stroke and breast cancer rise with age
• Cardiovascular risk factors: High blood pressure, high cholesterol, diabetes mellitus, smoking, obesity, a family history of early heart attack or atrial fibrillation
• Migraine or severe headaches: Especially migraine with aura, because of the theoretical increase in stroke risk
• Fibroids or endometriosis: Pre-existing uterine fibroids or endometriosis may be stimulated by the estrogenic activity of tibolone
• Previous endometrial hyperplasia: Even if treated
• Benign breast disease or dense breast tissue: Regular breast examination and mammography are recommended
• Gallbladder disease: A history of gallstones or gallbladder surgery
• Liver impairment or previous cholestatic jaundice
• Diabetes mellitus: Close monitoring of blood glucose may be appropriate
• Systemic lupus erythematosus (SLE)
• Epilepsy
• Asthma
• Otosclerosis

Regular medical follow-up is essential while taking Tibolon Aristo. Most guidelines recommend an annual clinical review that includes a targeted history (for unscheduled bleeding, breast changes, symptoms of thrombosis or stroke), a blood pressure measurement, a clinical breast examination and age-appropriate breast screening. Cervical screening and gynaecological examination should continue according to national screening programmes. If any new symptoms develop between visits — in particular, any new vaginal bleeding, a breast lump, calf swelling or pain, sudden chest pain or shortness of breath, severe headache, sudden visual disturbance, or weakness of one side of the body — you should stop tibolone and seek medical attention immediately.

Tibolone should be discontinued at least four to six weeks before any planned major surgery that carries a high risk of venous thromboembolism (for example, orthopaedic surgery or abdominal procedures requiring prolonged immobilisation). In emergencies where surgery cannot be delayed, thromboprophylaxis with heparin or low-molecular-weight heparin should be considered by the surgical team. Tibolone should not be restarted until the patient is fully mobile.

Pregnancy and Breastfeeding

Tibolon Aristo is intended exclusively for postmenopausal women. Pregnancy is therefore not expected to occur during treatment. However, if pregnancy is discovered while taking tibolone — for example, if the menopausal status was incorrectly assumed — the medicine must be stopped immediately and the pregnancy discussed with a gynaecologist. The limited available data on tibolone exposure in pregnancy do not suggest a specific teratogenic effect, but as with all hormonal medicines, unnecessary exposure should be avoided.

Tibolone is contraindicated during breastfeeding. It is not known to what extent tibolone and its metabolites pass into human breast milk, but systemic steroidal hormone exposure of a nursing infant is not acceptable. Women who choose to continue breastfeeding should not start tibolone, and alternative symptom-management strategies should be used.

How Does Tibolon Aristo Interact with Other Drugs?

Tibolone is metabolised by the liver, so medicines that induce or inhibit hepatic enzymes can change its blood levels. Enzyme inducers such as rifampicin, carbamazepine, phenytoin, phenobarbital and St. John's Wort may reduce the effectiveness of tibolone. Tibolone may also increase the anticoagulant effect of warfarin. Always tell your doctor and pharmacist about every prescription medicine, over-the-counter product, supplement and herbal remedy you use.

Drug interactions with tibolone are mostly of two types. The first is pharmacokinetic, where another medicine changes how quickly tibolone and its three active metabolites are broken down, mainly by cytochrome P450 enzymes and by phase II sulphation and glucuronidation in the liver and gut wall. The second type is pharmacodynamic, where another medicine either adds to or counteracts the hormonal effects of tibolone — for example in the case of coagulation or blood glucose control.

Enzyme-inducing medicines can substantially shorten the half-life of tibolone's metabolites and lower their blood concentration. Over weeks of combined use this may reduce symptom control and bone protection. Patients who need long-term antiepileptic therapy, tuberculosis therapy, or antiretroviral regimens containing strong enzyme inducers should discuss the likely impact on tibolone with their prescriber; in some cases an alternative symptom-management strategy is preferable to increasing the tibolone dose, because dose escalation has not been systematically studied.

Conversely, potent inhibitors of CYP3A4 — for example ketoconazole, itraconazole, clarithromycin, ritonavir, or grapefruit juice in very large quantities — may increase exposure to tibolone metabolites. The clinical significance of this interaction is less well characterised than with enzyme induction, and routine dose reduction is not recommended, but women using these medicines should be monitored more closely for estrogenic side effects such as breast tenderness, fluid retention or breakthrough bleeding.

Tibolone may enhance the anticoagulant effect of warfarin, with a measurable rise in the International Normalised Ratio (INR) reported in some women shortly after starting or stopping tibolone. Women on warfarin should have their INR checked more frequently during the first few weeks of tibolone therapy and whenever the tibolone dose is changed or discontinued. The interaction with direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban or dabigatran is less clearly defined, but women using these medicines after a previous thromboembolic event should generally avoid tibolone altogether, because a past VTE is itself a contraindication.

Potential Drug Interactions

The table above lists the interactions most commonly highlighted in the European Medicines Agency Summary of Product Characteristics and in national formularies such as the British National Formulary. It is not exhaustive. Because tibolone is used for many years in many women, and because women in midlife often take several long-term medicines for blood pressure, thyroid, bone health, mental health and chronic pain, every new prescription while on tibolone should trigger a brief interaction check by the prescriber or pharmacist.

What Is the Correct Dosage of Tibolon Aristo?

The standard dose of Tibolon Aristo is one 2.5 mg tablet by mouth once a day, taken at about the same time each day with water and without a tablet-free interval. Treatment is continuous, not cyclical. The dose is the same in all indications and is not routinely adjusted according to body weight. Do not change the dose without medical advice.

Tibolone has a single, fixed daily dose of 2.5 mg. Unlike some conventional HRT regimens, there is no cyclical schedule and no tablet-free interval: the same dose is taken every day of the month, continuously, for as long as treatment remains clinically justified. The simplicity of this regimen is one of the practical advantages of tibolone and is particularly helpful for women who found cyclical bleeding on sequential HRT distressing.

Your doctor will confirm that you are a suitable candidate before issuing the first prescription. The minimum time since the last natural menstrual period should be at least 12 months; starting earlier increases the risk of irregular bleeding and may increase the risk of endometrial hyperplasia. Women who have had a surgical menopause (bilateral oophorectomy) or premature ovarian insufficiency can start tibolone earlier, on specialist advice, because their hormonal milieu is already postmenopausal.

Adults (Postmenopausal Women)

Children and Adolescents

Elderly Patients

Hepatic and Renal Impairment

Missed Dose

If you forget to take your Tibolon Aristo tablet at the usual time, take it as soon as you remember on the same day. However, if you only remember the next day, skip the missed dose and continue with your normal schedule the following day. Do not take two tablets in one day to make up for a missed dose, because this does not improve symptom control and may increase the risk of side effects such as breast tenderness or breakthrough bleeding.

Missing the occasional single dose is unlikely to cause noticeable symptoms. Missing tibolone for several consecutive days, however, may lead to a temporary return of hot flushes, night sweats or mood changes until regular dosing is resumed and steady-state blood levels of the metabolites are rebuilt. If you are finding it difficult to remember your daily tablet, consider setting a fixed reminder, using a weekly pill organiser, or pairing the dose with a daily habit such as brushing your teeth or taking breakfast.

Overdose

What Are the Side Effects of Tibolon Aristo?

Most women tolerate tibolone well, and common side effects — abdominal discomfort, weight change, breast tenderness and breakthrough bleeding — tend to improve within the first six months. Serious but rare risks include breast cancer, endometrial cancer, ovarian cancer, ischaemic stroke and venous thromboembolism. These serious risks shape the decision to start, continue or stop tibolone therapy.

Like all medicines, Tibolon Aristo can cause side effects, although not every woman will experience them. Side effects are conventionally reported by frequency: very common (more than 1 in 10 women), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1000), and rare (fewer than 1 in 1000). The figures below are drawn from the pooled clinical trial programme and post-marketing surveillance of tibolone, as summarised in the European Medicines Agency documentation and in peer-reviewed pharmacovigilance reports.

Many of the more common side effects are related to the estrogenic activity of tibolone metabolites and tend to resolve as the body adapts over the first three to six months of treatment. Vaginal bleeding, in particular, is most often innocent breakthrough bleeding during this run-in period, and does not necessarily mean anything is wrong — but because bleeding can also be an early sign of endometrial pathology, it must be discussed with your doctor and investigated if it persists or returns.

Serious adverse events associated with tibolone include breast cancer, endometrial cancer, ovarian cancer, stroke and venous thromboembolism. These are uncommon as absolute events over a few years of use, but the relative increase is clinically meaningful and is the main reason why tibolone is a prescription-only medicine with strict indications and regular review. Any possible symptom of these serious events — a new breast lump, unexpected vaginal bleeding, a painful swollen calf, sudden chest pain or shortness of breath, sudden weakness or speech difficulty — must trigger prompt medical assessment.

Women and their clinicians are encouraged to report any suspected adverse reaction to the national pharmacovigilance system (for example, the MHRA Yellow Card scheme in the UK, the EMA EudraVigilance system in the European Economic Area, or FDA MedWatch for jurisdictions that register tibolone). Systematic reporting over decades has refined the safety profile of tibolone and continues to inform its appropriate use.

How Should You Store Tibolon Aristo?

Store Tibolon Aristo in its original blister packaging at room temperature, not above 25°C (77°F), in a cool dry place and out of reach of children. Do not use the tablets after the expiry date printed on the blister or carton, and do not dispose of them in household waste or wastewater.

Tibolone is moisture- and light-sensitive, and Tibolon Aristo tablets are therefore supplied in sealed aluminium blister strips inside an outer carton. The blister packaging protects the tablets from humidity and from light exposure, and is designed to keep them stable until the printed expiry date. Keep tablets in the blister until you are ready to take them; do not transfer them to a different container, because this removes the built-in moisture and light barrier and can shorten the effective shelf life.

The recommended storage temperature is below 25°C (77°F). Tibolon Aristo does not need to be kept in a refrigerator. Avoid storing tablets on a bathroom shelf, next to a radiator, in a car glove compartment in summer, or in direct sunlight on a windowsill, because fluctuating heat and humidity can gradually degrade the active substance.

Keep Tibolon Aristo out of the sight and reach of children at all times. Tablets are small and may be mistaken for sweets. Accidental ingestion of tibolone by a child is a medical emergency, because even though acute toxicity is low, a hormonal exposure in a child must be assessed by a paediatrician. A locked medicine cabinet or a high shelf that children cannot reach is strongly recommended.

Do not use Tibolon Aristo after the expiry date shown on the outer carton and blister. The expiry date refers to the last day of that month. Expired tibolone tablets may have reduced potency and may no longer provide reliable symptom control or bone protection. If you discover expired or unwanted tablets at home, return them to a community pharmacy for safe disposal rather than throwing them in the bin or flushing them down the toilet.

What Does Tibolon Aristo Contain?

Each Tibolon Aristo tablet contains 2.5 mg of the active substance tibolone together with standard pharmaceutical excipients including lactose monohydrate, potato starch, magnesium stearate and ascorbyl palmitate. The tablets are small, white and round, and are scored for identification rather than routine splitting.

The active substance in Tibolon Aristo is tibolone 2.5 mg per tablet. Tibolone is a synthetic steroid, chemically a 19-nor-testosterone derivative, with the chemical name (7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one. Following oral administration, tibolone is rapidly absorbed from the gastrointestinal tract and extensively metabolised. Three pharmacologically active metabolites account for most of its clinical effect: the 3α-hydroxy and 3β-hydroxy metabolites (predominantly estrogenic) and the delta-4 isomer (predominantly progestogenic and weakly androgenic). This unique metabolic profile is the basis of its tissue-selective action.

In addition to the active substance, Tibolon Aristo tablets contain inactive ingredients (excipients) that are required to ensure tablet stability, uniform dosing and reliable dissolution in the gut. These typically include lactose monohydrate as a diluent, potato starch or pregelatinised starch as a disintegrant, magnesium stearate as a lubricant, and ascorbyl palmitate as an antioxidant to protect the active substance from oxidative degradation. A small amount of colloidal silicon dioxide may be used to improve flow properties during manufacture. The exact excipient list for your pack is printed in the patient information leaflet inside the carton; always check this if you are avoiding specific ingredients.

Women with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take Tibolon Aristo because of its lactose content. For most patients, however, the amount of lactose in one tablet (a few milligrams) is not clinically significant, even in common adult lactose intolerance. If you have a documented allergy or intolerance to any of the excipients — including rare reactions to maize or potato starch derivatives — discuss this with your pharmacist before the first dose.

Tibolon Aristo tablets are not gluten-containing in their standard formulation, and are suitable for women with coeliac disease, although you should always confirm the current ingredient list on your pack. The tablets are also free from artificial colours in the standard strength. The round, white, uncoated appearance of the tablet makes it easy to recognise and is consistent with the reference tibolone preparations used in clinical trials.

Frequently Asked Questions About Tibolon Aristo